DexCom, Inc. Forecast, price target & analysts
DexCom, Inc. Target price 2025 - Analyst rating & recommendation
DexCom, Inc. Classifications & Recommendation:
DexCom, Inc. Price Target
| Target Price | $104.04 |
| Price | $80.17 |
| Potential | 29.77% |
| Number of Estimates | 29 |
| 29 Analysts have issued a price target DexCom, Inc. 2026 . The average DexCom, Inc. target price is $104.04. This is 29.77% higher than the current stock price. The highest price target is $126.00 57.17% , the lowest is $87.08 8.62% . | |
| A rating was issued by 34 analysts: 29 Analysts recommend DexCom, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the DexCom, Inc. stock has an average upside potential 2026 of 29.77% . Most analysts recommend the DexCom, Inc. stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2030
31 Analysts have issued a sales forecast DexCom, Inc. 2025 . The average DexCom, Inc. sales estimate is $4.7b . This is 9.47% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.9b 14.84% , the lowest is $4.5b 4.10% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $4.0b | 11.34% |
|---|---|---|
| 2025 | $4.7b | 16.74% |
| 2026 | $5.4b | 15.42% |
| 2027 | $6.2b | 14.72% |
| 2028 | $7.2b | 15.29% |
| 2029 | $7.9b | 10.00% |
| 2030 | $8.5b | 7.30% |
25 Analysts have issued an DexCom, Inc. EBITDA forecast 2025. The average DexCom, Inc. EBITDA estimate is $1.4b . This is 47.84% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.5b 61.05% , the lowest is $1.2b 26.07% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $871m | 39.97% |
|---|---|---|
| 2025 | $1.4b | 56.68% |
| 2026 | $1.7b | 25.86% |
| 2027 | $2.1b | 20.55% |
| 2028 | $2.6b | 27.28% |
| 2029 | $3.0b | 15.36% |
| 2030 | $3.2b | 3.68% |
EBITDA Margin
| 2024 | 21.60% | 25.72% |
|---|---|---|
| 2025 | 28.99% | 34.20% |
| 2026 | 31.62% | 9.07% |
| 2027 | 33.22% | 5.06% |
| 2028 | 36.68% | 10.42% |
| 2029 | 38.46% | 4.85% |
| 2030 | 37.17% | 3.35% |
30 DexCom, Inc. Analysts have issued a net profit forecast 2025. The average DexCom, Inc. net profit estimate is $812m . This is 42.10% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $881m 54.20% , the lowest is $749m 31.14% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $576m | 6.41% |
|---|---|---|
| 2025 | $812m | 40.95% |
| 2026 | $1.0b | 24.96% |
| 2027 | $1.3b | 23.25% |
| 2028 | $1.5b | 22.66% |
| 2029 | $1.8b | 16.62% |
| 2030 | $1.9b | 5.42% |
Net Margin
| 2024 | 14.29% | 4.43% |
|---|---|---|
| 2025 | 17.25% | 20.74% |
| 2026 | 18.68% | 8.29% |
| 2027 | 20.06% | 7.39% |
| 2028 | 21.35% | 6.43% |
| 2029 | 22.63% | 6.00% |
| 2030 | 22.24% | 1.72% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
30 Analysts have issued a DexCom, Inc. forecast for earnings per share. The average DexCom, Inc. EPS is $2.07 . This is 47.86% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.25 60.71% , the lowest is $1.91 36.43% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $1.40 | 10.24% |
|---|---|---|
| 2025 | $2.07 | 47.86% |
| 2026 | $2.59 | 25.12% |
| 2027 | $3.19 | 23.17% |
| 2028 | $3.91 | 22.57% |
| 2029 | $4.56 | 16.62% |
| 2030 | $4.81 | 5.48% |
P/E ratio
| Current | 57.26 | 30.52% |
|---|---|---|
| 2025 | 38.72 | 32.38% |
| 2026 | 30.98 | 19.99% |
| 2027 | 25.14 | 18.85% |
| 2028 | 20.49 | 18.50% |
| 2029 | 17.57 | 14.25% |
| 2030 | 16.67 | 5.12% |
Based on analysts' sales estimates for 2025, the DexCom, Inc. stock is valued at an EV/Sales of 6.59 and an P/S ratio of 6.68 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 7.21 | 3.74% |
|---|---|---|
| 2025 | 6.59 | 8.64% |
| 2026 | 5.71 | 13.36% |
| 2027 | 4.97 | 12.83% |
| 2028 | 4.31 | 13.26% |
| 2029 | 3.92 | 9.09% |
| 2030 | 3.66 | 6.80% |
P/S ratio
| Current | 7.31 | 2.89% |
|---|---|---|
| 2025 | 6.68 | 8.65% |
| 2026 | 5.79 | 13.36% |
| 2027 | 5.04 | 12.83% |
| 2028 | 4.37 | 13.26% |
| 2029 | 3.98 | 9.09% |
| 2030 | 3.71 | 6.80% |
Current DexCom, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Aug 01 2025 |
| Raymond James |
Strong Buy
➜
Strong Buy
|
Unchanged | Jul 31 2025 |
| Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
| UBS |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 30 2025 |
| Mizuho |
Outperform
➜
Outperform
|
Unchanged | Jul 16 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Aug 01 2025 |
|
Unchanged
Raymond James:
Strong Buy
➜
Strong Buy
|
Jul 31 2025 |
|
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jul 31 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Jul 31 2025 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Jul 31 2025 |
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Jul 30 2025 |
|
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Jul 16 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
